https://www.selleckchem.com/products/amg-232.html
orting long-term symptoms and whether higher symptoms of diarrhea in early illness presages deterioration. Real-world data assessing outcomes of immunocompromised patients treated with ceftolozane/tazobactam (C/T) are limited. This study evaluated treatment and clinical outcomes of immunocompromised patients receiving C/T for multidrug-resistant (MDR) . This was a 14-center retrospective cohort study of adult immunocompromised inpatients treated for ≥24 hours with C/T for MDR infections. Patients were defined as immunocompromised if the
Gefällt mir
Kommentar
Teilen
